Evaluation of Aortic Calcification With Lanthanum Carbonate vs. Calcium‐Based Phosphate Binders in Maintenance Hemodialysis Patients With Type 2 Diabetes Mellitus: An Open‐Label Randomized Controlled Trial

Therapeutic Apheresis and Dialysis - Tập 18 Số 4 - Trang 353-360 - 2014
Kentaro Wada1,2, Yuko Wada1,2
1Department of Internal Medicine, Central Hospital, Hiroshima, Japan
2Division of Nephrology and Dialysis, Nippon Kokan Fukuyama Hospital, Hiroshima, Japan

Tóm tắt

AbstractVascular calcification (VC) contributes to cardiovascular disease in hemodialysis (HD) patients, especially with diabetes mellitus (DM) complications. No randomized studies have been published regarding the effect of lanthanum carbonate (LC) on VC progression in DM patients. The aim of this study was to evaluate the effects of lanthanum carbonate on the progression of VC in HD patients with type 2 DM. We conducted a randomized controlled trial comparing LC with calcium carbonate (CC) in 43 HD patients at a single dialysis center. Estimations of aortic calcification index (ACI) by abdominal computed tomography were performed twice for each patient (at baseline and 12 months). Forty‐one patients completed the study (19 LC, 22 CC). When ACI at baseline was ≦0.48 (median of baseline ACI), median change in ACI (Δ%ACI) was 20.44 (11.50–36.80%) in the LC group, and 40.00 (33.30–92.60%) in the CC group (P = 0.026). On the other hand, when ACI at baseline was >0.48, the median change in ACI (Δ%ACI) was 6.42 (3.13–24.40%) in the LC group, and 8.08 (5.68–12.20%) in the CC group (P = 1.000). Serum markers of chronic kidney disease‐mineral and bone disorder (CKD‐MBD), HbA1c, dose of vitamin D analogues, and side‐effects of medications did not change in either group throughout the study except int‐PTH increased in the LC group. This study indicated that administration of LC inhibited the progression of VC in patients receiving HD for type 2 DM, only in cases of slight VC compared with CC.

Từ khóa


Tài liệu tham khảo

10.1046/j.1523-1755.2001.060002472.x

10.1016/0002-9343(79)91118-5

10.1177/039139889301600107

10.1007/s10157-011-0517-y

10.1053/j.ajkd.2006.12.017

10.1093/ndt/gfg414

10.1053/ajkd.2001.27396

10.1111/j.1744-9987.2007.00540.x

10.1053/ajkd.1998.v31.pm9531176

10.1056/NEJM200005183422003

10.1053/ajkd.2001.27394

10.1016/S0735-1097(01)01781-8

10.1093/ndt/gfh125

10.1046/j.1523-1755.2002.00434.x

10.1111/j.1523-1755.2005.00600.x

Locatelli F, 2003, Lanthanum carbonate (Shire), Idrugs, 6, 688

10.1111/j.1744-9987.2007.00541.x

10.1159/000149239

10.5414/CNP72252

10.1093/ndt/gfn737

10.1002/jcb.22348

10.1111/j.1440-1797.2010.01412.x

10.1159/000075807

10.1159/000226225

10.1007/s00125-002-0920-8

10.1007/s13340-012-0069-8

10.1046/j.1523-1755.1999.07163.x

10.1161/01.ATV.21.3.421

10.3181/0811-RM-346

10.1177/147323000903700329

10.1159/000112542

10.1093/ndt/15.7.1014

10.1016/S0085-2538(15)47156-X

10.1111/1744-9987.12037

10.1111/1744-9987.12043

Thông tin
Thông tin xuất bản

Therapeutic Apheresis and Dialysis

Tập 18 Số 4

353-360

Thông tin tác giả